PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month Low Following Insider Selling

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) shares hit a new 52-week low on Thursday following insider selling activity. The stock traded as low as $58.37 and last traded at $58.2550, with a volume of 547,250 shares changing hands. The stock had previously closed at $60.23.

Specifically, VP Mark Boulding sold 2,812 shares of the business’s stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $61.88, for a total value of $174,006.56. Following the completion of the sale, the vice president owned 105,272 shares in the company, valued at approximately $6,514,231.36. The trade was a 2.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analysts Set New Price Targets

A number of analysts have recently weighed in on PTCT shares. Leerink Partners started coverage on PTC Therapeutics in a research report on Monday, September 14th. They issued an “outperform” rating and a $98.00 price objective for the company. Citigroup upped their target price on PTC Therapeutics from $108.00 to $109.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. Royal Bank Of Canada increased their price target on PTC Therapeutics from $75.00 to $77.00 and gave the company a “sector perform” rating in a research note on Friday, October 30th. Truist Financial initiated coverage on PTC Therapeutics in a report on Friday, October 16th. They issued a “hold” rating and a $62.00 price target for the company. Finally, Cantor Fitzgerald boosted their price target on PTC Therapeutics from $130.00 to $137.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $99.23.

View Our Latest Stock Report on PTCT

PTC Therapeutics Stock Performance

The stock has a 50-day moving average price of $63.26 and a 200 day moving average price of $69.87.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76). The company had revenue of $357.81 million for the quarter, compared to analysts’ expectations of $306.43 million. The company’s quarterly revenue was up 69.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.20 earnings per share. Analysts predict that PTC Therapeutics, Inc. will post 0.49 earnings per share for the current fiscal year.

PTC Therapeutics announced that its board has approved a stock buyback plan on Tuesday, November 3rd that authorizes the company to repurchase $500 million in shares. This buyback authorization authorizes the biopharmaceutical company to buy up to 9.8% of its stock through open market purchases. Share buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Allworth Financial LP acquired a new stake in PTC Therapeutics in the second quarter worth $67,000. Harbor Investment Advisory LLC bought a new position in shares of PTC Therapeutics during the second quarter worth $81,000. EverSource Wealth Advisors LLC boosted its position in shares of PTC Therapeutics by 16.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 151 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of PTC Therapeutics in the 2nd quarter valued at $112,000. Finally, Jacobi Capital Management LLC acquired a new position in shares of PTC Therapeutics in the 3rd quarter valued at $91,000.

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.

Featured Stories

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.